Finland · Delayed Price · Currency is EUR Remedy Entertainment Oyj Statistics
Total Valuation
HEL:REMEDY has a market cap or net worth of EUR 185.37 million. The enterprise value is 174.25 million.
| Market Cap | 185.37M |
| Enterprise Value | 174.25M |
Important Dates
The next confirmed earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HEL:REMEDY has 13.59 million shares outstanding. The number of shares has increased by 0.64% in one year.
| Current Share Class | 13.59M |
| Shares Outstanding | 13.59M |
| Shares Change (YoY) | +0.64% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 32.80% |
| Owned by Institutions (%) | 20.88% |
| Float | 9.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 109.12 |
| PS Ratio | 3.12 |
| PB Ratio | 3.28 |
| P/TBV Ratio | 6.47 |
| P/FCF Ratio | 279.18 |
| P/OCF Ratio | 41.08 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 40.67, with an EV/FCF ratio of 262.42.
| EV / Earnings | -13.37 |
| EV / Sales | 2.93 |
| EV / EBITDA | 40.67 |
| EV / EBIT | n/a |
| EV / FCF | 262.42 |
Financial Position
The company has a current ratio of 3.25, with a Debt / Equity ratio of 0.32.
| Current Ratio | 3.25 |
| Quick Ratio | 3.25 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 4.26 |
| Debt / FCF | 27.51 |
| Interest Coverage | 0.04 |
Financial Efficiency
Return on equity (ROE) is -20.83% and return on invested capital (ROIC) is 0.14%.
| Return on Equity (ROE) | -20.83% |
| Return on Assets (ROA) | 0.04% |
| Return on Invested Capital (ROIC) | 0.14% |
| Return on Capital Employed (ROCE) | 0.08% |
| Weighted Average Cost of Capital (WACC) | 9.70% |
| Revenue Per Employee | 153,773 |
| Profits Per Employee | -33,669 |
| Employee Count | 387 |
| Asset Turnover | 0.64 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.82% in the last 52 weeks. The beta is 1.05, so HEL:REMEDY's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -26.82% |
| 50-Day Moving Average | 12.86 |
| 200-Day Moving Average | 13.91 |
| Relative Strength Index (RSI) | 51.51 |
| Average Volume (20 Days) | 11,662 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HEL:REMEDY had revenue of EUR 59.51 million and -13.03 million in losses. Loss per share was -0.96.
| Revenue | 59.51M |
| Gross Profit | 47.27M |
| Operating Income | 56,000 |
| Pretax Income | -15.70M |
| Net Income | -13.03M |
| EBITDA | 2.95M |
| EBIT | 56,000 |
| Loss Per Share | -0.96 |
Balance Sheet
The company has 29.40 million in cash and 18.27 million in debt, with a net cash position of 11.13 million or 0.82 per share.
| Cash & Cash Equivalents | 29.40M |
| Total Debt | 18.27M |
| Net Cash | 11.13M |
| Net Cash Per Share | 0.82 |
| Equity (Book Value) | 56.59M |
| Book Value Per Share | 4.16 |
| Working Capital | 31.00M |
Cash Flow
In the last 12 months, operating cash flow was 4.51 million and capital expenditures -3.85 million, giving a free cash flow of 664,000.
| Operating Cash Flow | 4.51M |
| Capital Expenditures | -3.85M |
| Depreciation & Amortization | 2.89M |
| Net Borrowing | -1.44M |
| Free Cash Flow | 664,000 |
| FCF Per Share | 0.05 |
Margins
Gross margin is 79.43%, with operating and profit margins of 0.09% and -21.90%.
| Gross Margin | 79.43% |
| Operating Margin | 0.09% |
| Pretax Margin | -26.39% |
| Profit Margin | -21.90% |
| EBITDA Margin | 4.96% |
| EBIT Margin | 0.09% |
| FCF Margin | 1.12% |
Dividends & Yields
HEL:REMEDY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.64% |
| Shareholder Yield | -0.64% |
| Earnings Yield | -7.03% |
| FCF Yield | 0.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for HEL:REMEDY is 16.75, which is 18.63% higher than the current price. The consensus rating is "Buy".
| Price Target | 16.75 |
| Price Target Difference | 18.63% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 10.37% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HEL:REMEDY has an Altman Z-Score of 4.95 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.95 |
| Piotroski F-Score | 6 |